You are here
The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
SBC: FasCure Therapeutics LLC Topic: NIAID
DESCRIPTION provided by applicant FasCure Therapeutics focuses on the development of adjuvant systems to generate prophylactic and therapeutic immune responses The major objective of this Phase STTR proposal is to reformulate a lead plague subunit vaccine with a novel adjuvant system to improve its protective efficacy Yersinia pestis is the causative agent of bubonic and pneumonic plague ...STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
SBC: Schell Games LLC Topic: NICHD
DESCRIPTION provided by applicant HIV disproportionately impacts minority adolescents and most of them have neither undergone HIV testing and counseling HTC nor know their status Adolescence is a andquot window of opportunityandquot to intervene with HIV behavior change interventions Challenges to implementing and disseminating some effective HIV prevention programs in adolescents may lim ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: Lumina Diagnostics, Inc. Topic: NICHD
DESCRIPTION provided by applicant We propose to develop a non invasive device to enable children with urea cycle disorders and their parents guardians and physicians to actively manage the disorder at home and improve outcomes in the clinic Urea cycle disorders UCD are inborn errors of metabolism that impair oneandapos s ability to convert ammonia NH a neurotoxin into urea which is ...STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
SBC: XFIBRA, LLC Topic: NHLBI
DESCRIPTION provided by applicant Activation of lung myofibroblasts LMF is responsible for the development of lung fibrosis in chronic lung diseases of all causes and remarkably LMF clearance by apoptosis may prevent development of lung fibrosis and lung injury and possibly allow recovery from reversal of lung fibrosis There is full agreement among tissue fibrosis experts that inhibiting o ...STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
SBC: CFD RESEARCH CORPORATION Topic: DHP16A001
Surgical simulations aiming to support surgeon practices and medical education have attracted enormous research effort over the last two decades. However, the physical reality, especially on simulating aggregated tissue interaction, is still unsatisfactory. In this proposed work, an open source surgery simulation framework, SoFMIS, will be utilized and enhanced with tissue interaction models to a ...STTR Phase I 2016 Department of DefenseDefense Health Agency
Infectious Disease Diagnostics and Differentiation of Viral vs. Bacterial Infections for Point of Care ApplicationsSBC: GeneCapture, Inc. Topic: CBD15C001
The modern warfighter faces the constant threat of endemic infections, multi-drug resistant bacteria and Biological Warfare Agents. In order to provide accurate front-line treatment that will curtail the overuse of antibiotics, a rapid and robust moleculaSTTR Phase I 2016 Department of DefenseOffice for Chemical and Biological Defense
Development of novel research tools and a database for mapping human mitochondrial tRNA modifications by mass spectrometrySBC: Ribonova Inc. Topic: R42
Summary In this fast track Phase I II STTR project a novel mass spectrometry method and a matched reagent kit will be developed for mapping modified nucleotides in human mitochondrial transfer RNA mt tRNA including the most abundant modification pseudouridine which hitherto has proved to be a technical challenge because it is an isomer of uridine These new research tools will be harnessed to build ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC. Topic: R
DESCRIPTION provided by applicant The ultimate goal of this project is to produce a broad spectrum drug for the treatment of viral infections caused by filoviruses Ebola and Marburg arenaviruses Lassa fever and rhabdoviruses rabies We and others have determined that efficient budding of these emerging human pathogens is dependent on the subversion of host proteins such as Nedd and t ...STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
SBC: ARIMA GENOMICS, INC. Topic: 172
DESCRIPTION provided by applicant Phenomenal advances in DNA sequencing technologies have enabled systematic identification of genetic variants in human individuals and the recent FDA marketing authorization of the first next generation genome sequencer signals the arrival of a new era of pharmacogenomics and personalized medicine Nevertheless DNA sequencing alone fails to provide complete i ...STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
SBC: VITALEX BIOSCIENCES LLC Topic: NIAID
DESCRIPTION provided by applicant Mucormycosis most commonly caused by Rhizopus oryzae is a life threatening infection that occurs in patients immunocompromised by diabetic ketoacidosis DKA neutropenia corticosteroid use and or increased serum iron Because of the rising prevalence of these risk factors the incidence of mucormycosis has risen Despite disfiguring surgery and aggressive ...STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health